Orgenesis to Sponsor and Present at ESGCT 20th Anniversary Congress
Orgenesis Inc. (ORGS) (“Orgenesis” or the “Company”), a development-stage company with a novel therapeutic technology dedicated to converting a patient’s own liver cells into functioning insulin-producing cells as a treatment for diabetes, is pleased to announce its participation and sponsorship at the European Society of Gene & Cell Therapy (“ESGCT”) 20 Anniversary Congress, to be held October 26-29, 2012 in Versailles, France.
Prof. Sarah Ferber, Chief Science Officer of Orgenesis, will serve as chair of the Adult Cell Reprogramming section and will give a presentation entitled “Transdifferentiation: autologous cell replacement therapy.”
“We are proud to support this year’s ESGCT congress and to be part of the global effort to advance the science and promise of gene and cell therapy,” commented Jacob BenArie, President and CEO of Orgenesis. “Our participation also provides us with an opportunity to update experts in the field on our research directed towards advancing a better treatment for diabetes.”
The European Society of Gene and Cell Therapy promotes basic and clinical research in gene therapy, cell therapy, and genetic vaccines by facilitating education, the exchange of information and technology and by serving as a professional adviser to stakeholder communities and regulatory bodies in Europe.
Orgenesis (OTCBB: ORGS) is a development stage company with a novel therapeutic technology that employs a molecular and cellular approach directed at converting a patient's own liver cells into functional insulin producing cells, as a treatment for diabetes. The Company believes that converting the diabetic patient's own tissue into insulin-producing cells overcomes the problem of donor shortage and removes the risk of transplant rejection. If successful, this could mean the end of diabetes, as we now know it. For more information visit: .
On Behalf of the BoardOrgenesis Inc.
Vered Caplan, Chairperson